Skip to content
Clinical Trials – home
Recruiting

Safety and tolerability study of sodium hydrogen carbonate and sodium dihydrogen phosphate suppository treatment in adult patients with chronic constipation

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical study examines the effects of Lecicarbon® E CO2-Laxans in people with chronic constipation. Chronic constipation is a condition where a person has two or fewer bowel movements per week, along with symptoms such as hard stools, incomplete evacuation feelings, or straining during bowel movements that persist for at least 6 months.

The purpose of this study is to evaluate how safe and well-tolerated Lecicarbon® E CO2-Laxans is when used as a long-term treatment. The medication is given as a suppository for rectal use and contains two active ingredients: sodium hydrogen carbonate and sodium dihydrogen phosphate. Patients may receive up to two units daily for a treatment period of up to 4 weeks.

During the study, participants will need to keep a diary to track their bowel movements and symptoms. The study will also look at how the treatment affects constipation symptoms and overall quality of life. The medication works by producing carbon dioxide, which helps stimulate bowel movements.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial evaluation

    Your participation begins with confirming that you meet the eligibility criteria, including being 18 years or older and having chronic constipation (two or fewer bowel movements per week) for at least 6 months

    If you are a woman of childbearing age, you will need to take a pregnancy test, which must be negative to participate

    You will need to stop any current constipation treatments you may be using

  2. Step 2

    Treatment period

    You will receive Lecicarbon® E CO2-Laxans in the form of suppositories for rectal use

    During the study period, you will need to maintain your current lifestyle and dietary habits without changes

    You will be required to maintain a patient diary to record your bowel movements and symptoms

  3. Step 3

    Monitoring and assessment

    Your progress will be tracked using a measure called complete spontaneous bowel movements (CSBM)

    You will complete questionnaires about your constipation symptoms using a tool called PAC-SYM

    Your quality of life will be evaluated using a questionnaire called PAC-QOL

  4. Step 4

    Study duration

    The study is scheduled to run from August 2025 to August 2026

    Your participation will help evaluate the safety and tolerability of long-term treatment with Lecicarbon® for chronic constipation

Who can join the trial?

8 criteria

  • Must be 18 years or older, can be male or female
  • Must be able to move independently or use a wheelchair. If paralyzed, only patients with paraplegia (paralysis of the lower body) can participate
  • Must have chronic constipation for at least 6 months, defined as: - Having two or fewer bowel movements per week - Having very hard stools at least 25% of the time - Feeling incomplete evacuation after at least 25% of the time - Straining during bowel movements at least 25% of the time
  • Must provide written consent for participation and sharing of personal data in anonymous form
  • Women who can become pregnant must have a negative pregnancy test at the first visit
  • Must stop any current constipation treatments before starting the study
  • Must agree not to change lifestyle and eating habits during the study period
  • Must be willing to maintain a patient diary according to study requirements

Who cannot join the trial?

14 criteria

  • Age below 18 years or above 65 years
  • Pregnancy or breastfeeding
  • History of inflammatory bowel disease (conditions causing inflammation in the intestines)
  • Current or recent use of medications that affect bowel movements
  • Known allergy or sensitivity to any components of Lecicarbon®
  • Severe liver or kidney disease
  • Active gastrointestinal bleeding
  • Recent abdominal surgery (within the last 3 months)
  • Current participation in other clinical trials
  • Inability to follow study procedures or provide informed consent
  • Severe mental health conditions that could affect compliance
  • History of colorectal cancer (cancer of the large intestine or rectum)
  • Uncontrolled high blood pressure or heart disease
  • Major medical conditions that could interfere with study participation
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lecicarbon is a medication used to treat chronic constipation. It works as a suppository that helps stimulate bowel movements in a natural way. The medication contains carbon dioxide-releasing ingredients that create gentle pressure in the rectum, which helps trigger the urge to have a bowel movement. This mechanical action is combined with a mild lubricating effect that makes it easier to pass stools.

What is already known about the treatment

Lecicarbon - A medication administered in suppository form used for the treatment of chronic constipation. This laxative works by releasing carbon dioxide when it comes into contact with intestinal moisture, which creates a gentle mechanical stimulus to promote bowel movement. The medication belongs to the class of stimulant laxatives and works locally in the rectum, making it particularly suitable for patients who need regular, predictable relief from constipation. Lecicarbon has been well-documented in medical literature as a safe option for long-term management of chronic constipation, with its mechanism of action being primarily physical rather than chemical.

Investigated diseases

Chronic Constipation - A persistent condition where bowel movements occur less frequently than normal, typically fewer than three times per week. It is characterized by hard, dry stools that are difficult to pass and often accompanied by straining during bowel movements. People with this condition may experience bloating, abdominal discomfort, and a sensation of incomplete evacuation. The condition can develop due to various factors including dietary habits, lifestyle, or underlying health issues. Chronic constipation differs from occasional constipation as it persists for several weeks or longer.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-522464-32-00Protocol codeATS_9711Estimated enrolment100 patientsSponsorAthenstaedt GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.